Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.

Nizar M. Tannir,Robert J. Motzer,Laurence Albiges,Elizabeth R. Plimack,Saby George,Thomas Powles,Frede Donskov,Brian I. Rini,Viktor Grünwald,Hans J. Hammers,Toni K. Choueiri,Howard Gurney,Scott S. Tykodi,Camillo Porta,Mauricio Burotto,Yoshihiko Tomita,Chung-Wei Lee,Chad Tang,David F. McDermott,Rana R. McKay

Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.

2021

313Background: First-line NIVO+IPI demonstrates superior survival and response benefits in intent-to-treat (ITT) patients (pts) with aRCC after long-term follow-up in the phase 3 CheckMate 214 tria...

Keywords:

Oncology
Ipilimumab
Renal cell carcinoma
Internal medicine
Checkmate
in patient
Medicine
Nivolumab
Sunitinib
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations